EXECUTIVE INTERVIEWS

  • Where Are The Most Valuable Lessons Learned?
    Where Are The Most Valuable Lessons Learned?

    I imagine George Yancopoulos, profiled on this month’s cover, to have gained some of his life’s wisdom in a similar fashion to most people — by trying new things.

  • Being A Multicultural Millennial Female In Pharma Manufacturing
    Being A Multicultural Millennial Female In Pharma Manufacturing

    Tawni Koutchesfahani, director of manufacturing strategy at Relypsa, says pharmaceutical manufacturing must diversify if it is to thrive. That means the recruitment and retention of more women and more millennials.

  • Chris Garabedian On How To Drive Drug Development
    Chris Garabedian On How To Drive Drug Development

    Drawing from his 27 years in the pharma industry, Chris Garabedian shares useful lessons for combining business savvy and scientific leadership in drug development.

  • How Wild Ideas Fuel Regeneron’s George Yancopoulos
    How Wild Ideas Fuel Regeneron’s George Yancopoulos

    An exclusive interview with George Yancopoulos who talks about why his partnership with Len Schleifer has lasted so long and how “wild ideas” have served as the underlying theme to Regeneron.

  • Industry Explorers Blaze On: Vicki Sato — The Biology Biz
    Industry Explorers Blaze On: Vicki Sato — The Biology Biz

    Beginning her career with the query — how does biology cause disease? — Vicki Sato progressed to business, turning scientific understanding into new therapeutic drugs. Sato has been a biopharma leader since the industry’s formative years, helping drive the growth of Biogen and Vertex, and she is still guiding new companies today.

  • A Six-Year Approach To Improving Clinical Trial Efficiencies
    A Six-Year Approach To Improving Clinical Trial Efficiencies

    According to Victoria DiBiaso, global head of clinical operations strategy and collaboration at Sanofi, “When it comes to improving trials, you have to look at protocol optimization. For us, that is where it all begins.

  • Lilly Uses Patient Awareness & Access To Cut Clinical Trial Timelines
    Lilly Uses Patient Awareness & Access To Cut Clinical Trial Timelines

    According to Anne White, Lilly’s VP of next generation development and project management, for the past three years the company has steadily worked toward finding a way to get its medicines to patients faster.

  • Kaleido Biosciences: The Opportunity That Pulled Michael Bonney Out Of Retirement
    Kaleido Biosciences: The Opportunity That Pulled Michael Bonney Out Of Retirement

    Michael Bonney discusses his new role as the CEO of a microbiome focused drug development startup — Kaleido Biosciences.

  • Industry Explorers Blaze On: Anna Protopapas
    Industry Explorers Blaze On: Anna Protopapas

    Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.

  • Alnylam – Poised To Deliver Its Breakthrough In 2018
    Alnylam – Poised To Deliver Its Breakthrough In 2018

    In 2018, Alnylam seems poised to deliver its first big breakthrough. John Maraganore, CEO, sat down with LSL Chief Editor, Rob Wright, to share his perspectives on Alnylam’s upcoming year — including the good, the bad, and everything in-between.

  • What’s Next For Seattle Genetics?
    What’s Next For Seattle Genetics?

    Clay Siegall, Ph.D., president, CEO, and chairman of Seattle Genetics, gives an exclusive interview about his company’s potential blockbuster, how they got to this point, and what’s next.

  • Quality Adds Empathy To Outsourcing
    Quality Adds Empathy To Outsourcing

    Vinita Kumar, VP of quality at Versartis, talks about how her philosophy on CMO collaboration has been field-tested. “Never does that importance of real collaboration reveal itself more than in hard times for your program when you need it most,” she says.

  • How Mesoblast Survived The Termination Of A Key Partnership, And Prospered
    How Mesoblast Survived The Termination Of A Key Partnership, And Prospered

    With TEVA Pharmaceuticals out of the picture, Mesoblast had to figure out how to survive. Due to hard work, Mesoblast found a way to save their company and here is how they did it. “The termination left us in a hole. We had to gather our thoughts, allocate resources, and prove that the technology worked.”

  • Navigating The Turbulent Waters From Discovery To Clinical
    Navigating The Turbulent Waters From Discovery To Clinical

    “A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.

More executive interviews

BEYOND THE PRINTED PAGE

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

More From Life Science Leader Blogs

@LIFESCILEADER1